Chemours Faces Multiple Securities Fraud Lawsuits

Class action claims allege manipulation of financial metrics for executive compensation, leading to significant stock price drops.

Kessler Topaz Meltzer & Check, LLP and Robbins Geller Rudman & Dowd LLP have filed class action lawsuits against The Chemours Company for securities fraud.
The lawsuits allege that Chemours and certain executives manipulated Free Cash Flow targets to maximize incentive compensation.
Chemours delayed its financial results and annual report filing, citing the need for additional time to complete year-end reporting and evaluate internal controls.
The company's stock price fell significantly following announcements of the delays and the administrative leave of key executives.
The Chemours Company's Audit Committee found efforts to manipulate financial metrics to meet Free Cash Flow targets, impacting executive compensation and financial reporting.